BACKGROUND/AIMS: Etanercept is a tumor necrosis factor-alpha antagonist used in inflammation-mediated conditions. Continuous venovenous hemofiltration (CVVH) has also been used in patients with inflammatory conditions. This study evaluated etanercept clearance using an in vitro CVVH model. METHODS: Etanercept clearance was assessed in vitro in bovine blood at 1-3 mg/l final serum concentration, and urea control at 750 mg/l. CVVH was performed using polyacrylonitrile, polysulfone, and polymethylmethacrylate filters at 3 l/h ultrafiltrate and 200 ml/min blood flow rates. Transmembrane clearance was estimated using sieving coefficient calculations, and adsorptive removal rate was approximated using a mass balance calculation. RESULTS: Urea sieving coefficient remained constant (1.04 +/- 0.01). Ultrafiltrate etanercept concentrations were undetectable (sieving coefficient < 0.02) and transmembrane and adsorptive clearances were negligible. CONCLUSION: Etanercept is not cleared appreciably by transmembrane or adsorptive mechanisms in CVVH using polyacrylonitrile, polysulfone, or polymethylmethacrylate hemofilters. Copyright 2009 S. Karger AG, Basel.
BACKGROUND/AIMS: Etanercept is a tumor necrosis factor-alpha antagonist used in inflammation-mediated conditions. Continuous venovenous hemofiltration (CVVH) has also been used in patients with inflammatory conditions. This study evaluated etanercept clearance using an in vitro CVVH model. METHODS: Etanercept clearance was assessed in vitro in bovine blood at 1-3 mg/l final serum concentration, and urea control at 750 mg/l. CVVH was performed using polyacrylonitrile, polysulfone, and polymethylmethacrylate filters at 3 l/h ultrafiltrate and 200 ml/min blood flow rates. Transmembrane clearance was estimated using sieving coefficient calculations, and adsorptive removal rate was approximated using a mass balance calculation. RESULTS:Urea sieving coefficient remained constant (1.04 +/- 0.01). Ultrafiltrate etanercept concentrations were undetectable (sieving coefficient < 0.02) and transmembrane and adsorptive clearances were negligible. CONCLUSION: Etanercept is not cleared appreciably by transmembrane or adsorptive mechanisms in CVVH using polyacrylonitrile, polysulfone, or polymethylmethacrylate hemofilters. Copyright 2009 S. Karger AG, Basel.
Authors: K R Cooke; G R Hill; A Gerbitz; L Kobzik; T R Martin; J M Crawford; J P Brewer; J L Ferrara Journal: Transplantation Date: 2000-07-27 Impact factor: 4.939
Authors: E F Yekebas; C F Eisenberger; H Ohnesorge; A Saalmüller; H A Elsner; M Engelhardt; A Gillesen; J Meins; M The; T Strate; C Busch; W T Knoefel; C Bloechle; J R Izbicki Journal: Crit Care Med Date: 2001-07 Impact factor: 7.598
Authors: Mariann D Churchwell; Deborah A Pasko; Imad F Btaiche; Jinesh C Jain; Bruce A Mueller Journal: Nephrol Dial Transplant Date: 2007-06-07 Impact factor: 5.992
Authors: K R Cooke; A Gerbitz; J M Crawford; T Teshima; G R Hill; A Tesolin; D P Rossignol; J L Ferrara Journal: J Clin Invest Date: 2001-06 Impact factor: 14.808
Authors: Stuart L Goldstein; Michael J G Somers; Michelle A Baum; Jordan M Symons; Patrick D Brophy; Douglas Blowey; Timothy E Bunchman; Cheryl Baker; Theresa Mottes; Nancy McAfee; Joni Barnett; Gloria Morrison; Kristine Rogers; James D Fortenberry Journal: Kidney Int Date: 2005-02 Impact factor: 10.612